Microvolt T-Wave Alternans and the Risk of Death or Sustained Ventricular Arrhythmias in Patients With Left Ventricular Dysfunction  by Bloomfield, Daniel M. et al.
M
D
i
D
P
E
J
N
a
P
(
o
a
c
f
p
v
m
W
N
C
f
R
o
N
s
I
M
s
I

F
w
2
Journal of the American College of Cardiology Vol. 47, No. 2, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Picrovolt T-Wave Alternans and the Risk of
eath or Sustained Ventricular Arrhythmias
n Patients With Left Ventricular Dysfunction
aniel M. Bloomfield, MD, FACC,* J. Thomas Bigger, MD, FACC,* Richard C. Steinman, AB,*
earila B. Namerow, PHD,* Michael K. Parides, PHD,* Anne B. Curtis, MD, FACC,†
lizabeth S. Kaufman, MD, FACC,‡ Jorge M. Davidenko, MD, FACC,§ Timothy S. Shinn, MD, FACC,
ohn M. Fontaine, MD, FACC¶
ew York and Syracuse, New York; Tampa, Florida; Cleveland, Ohio; Ypsilanti, Michigan;
nd Philadelphia, Pennsylvania
OBJECTIVES This study hypothesized that microvolt T-wave alternans (MTWA) improves selection of
patients for implantable cardioverter-defibrillator (ICD) prophylaxis, especially by identifying
patients who are not likely to benefit.
BACKGROUND Many patients with left ventricular dysfunction are now eligible for prophylactic ICDs, but
most eligible patients do not benefit; MTWA testing has been proposed to improve patient
selection.
METHODS Our study was conducted at 11 clinical centers in the U.S. Patients were eligible if they had
a left ventricular ejection fraction (LVEF)0.40 and lacked a history of sustained ventricular
arrhythmias; patients were excluded for atrial fibrillation, unstable coronary artery disease, or
New York Heart Association functional class IV heart failure. Participants underwent an
MTWA test and then were followed for about two years. The primary outcome was all-cause
mortality or non-fatal sustained ventricular arrhythmias.
RESULTS Ischemic heart disease was present in 49%, mean LVEF was 0.25, and 66% had an abnormal
MTWA test. During 20 6 months of follow-up, 51 end points (40 deaths and 11 non-fatal
sustained ventricular arrhythmias) occurred. Comparing patients with normal and abnormal
MTWA tests, the hazard ratio for the primary end point was 6.5 at two years (95%
confidence interval 2.4 to 18.1, p  0.001). Survival of patients with normal MTWA tests
was 97.5% at two years. The strong association between MTWA and the primary end point
was similar in all subgroups tested.
CONCLUSIONS Among patients with heart disease and LVEF 0.40, MTWA can identify not only a
high-risk group, but also a low-risk group unlikely to benefit from ICD prophylaxis. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.026Coll Cardiol 2006;47:456–63) © 2006 by the American College of Cardiology Foundation
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Matients with impaired left ventricular ejection fraction
LVEF) have an increased risk of sudden death, even on
ptimal medical therapy, and many of these deaths are
ttributed to sustained ventricular arrhythmias. Implantable
ardioverter-defibrillators (ICDs) effectively prevent death
rom ventricular arrhythmias (1–5), but, unfortunately, most
atients with left ventricular dysfunction who die from
entricular arrhythmias die with their first cardiac arrest
From the *Columbia University Medical Center, New York, New York; †Depart-
ent of Medicine, University of South Florida, Tampa, Florida; ‡MetroHealth, Case
estern Reserve University, Cleveland, Ohio; §New York Heart Center, Syracuse,
ew York; Michigan Heart PC, Ypsilanti, Michigan; and ¶Drexel University
ollege of Medicine, Philadelphia, Pennsylvania. Supported by grants HL-64862
rom the National Heart, Lung, and Blood Institute, 5 M01 RR-00645, Division of
esearch Resources, General Clinical Research Centers Program, National Institutes
f Health, Bethesda, Maryland; a grant from the Doris Duke Charitable Foundation,
ew York, New York; and a grant from Cambridge Heart Inc., Bedford, Massachu-
etts. The initial funding for the pilot phase of this study came from Cambridge Heart
nc. (Bedford, Massachusetts), the manufacturer of the equipment used to measure
TWA. The majority of funding (80%) for the multicenter phase of this study was
upported by an R01 grant (HL-64862) from the National Heart, Lung, and Blood
nstitute of the National Institutes of Health. Overall, Cambridge Heart provided
10% of the funding for this study (the other 10% came from the Doris Duke
oundation). Dr. Bloomfield previously served as a consultant to Cambridge Heart
hen this technology was first being developed.t
Manuscript received August 29, 2005; revised manuscript received October 21,
005, accepted November 1, 2005.6,7). To bring the benefit of ICD therapy to patients who
ave not yet had episodes of sustained ventricular arrhyth-
ias requires identification of patients at substantial risk of
ife-threatening arrhythmic events.
During the past 10 years, several randomized controlled
rials demonstrated benefit for ICD prophylaxis in selected
atients. In 2002, the Multicenter Automatic Defibrillator
mplantation Trial II (MADIT II) and, in 2005, the
udden Cardiac Death in Heart Failure Trial (SCD-HeFT)
emonstrated that ICD prophylaxis can improve survival in
atients selected primarily by a substantially reduced LVEF
8,9). However, the absolute benefit of ICD prophylaxis on
ortality is relatively small (5.6% or 7.2%) in patients
elected using LVEF (10). Thus, only a few of the ICDs
mplanted prophylactically ever deliver appropriate therapy.
he Center for Medicare and Medicaid Services (CMS) has
ccepted the scientific validity of these ICD prophylaxis
rials, but has recognized the need for better risk stratifica-
ion (11) because the inconvenience, adverse effects, and
ost of implanting ICDs in all patients who meet the
ADIT II or SCD-HeFT criteria are substantial (10,12).
Microvolt T-wave alternans (MTWA) testing can iden-ify patients at increased risk for sudden cardiac death.
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January 17, 2006:456–63 Microvolt T-Wave Alternans and ICD Prophylaxisnimal (13) and human studies (14–22) demonstrated a
trong association between MTWA and increased risk of
entricular tachyarrhythmias and sudden cardiac death.
hile the early studies evaluated patients with a history of
rior arrhythmias (14–16), only three small clinical studies
ave evaluated patients without prior arrhythmic events who
re eligible for prophylactic ICDs (17,18,21). Remarkably,
he survival of patients with a normal MTWA in these
tudies was excellent (corresponding to a very low false
egative rate) (16–22). Accordingly, we designed and con-
ucted a large, prospective, multicenter study supported by
he National Institutes of Health to test the hypothesis that
n patients with either ischemic heart disease or non-
schemic cardiomyopathy and LVEF 0.40, an abnormal
TWA would be associated with an increased risk of death
nd non-fatal arrhythmic events, and a normal MTWA
ould be associated with an excellent prognosis.
ETHODS
atient selection. After a pilot feasibility phase of this
tudy at a single center and after receiving funding from the
ational Heart, Lung, and Blood Institute, our epidemio-
ogic study was conducted at 11 clinical centers in the U.S.
hese centers represented a mixture of large community-
ased cardiology private practices, academic heart failure
enters, and academic cardiology practices. The institutional
eview board at each clinical center approved the protocol,
nd written informed consent was obtained from all patients
efore their enrollment. The first patient was enrolled in
ovember 1996 and the last in March 2003. Patients were
ligible to participate if they were at least 18 years of age,
ad an LVEF0.40, had no history of sustained ventricular
rrhythmia, and gave informed consent. Because MTWA
an only be measured during a regular atrial rhythm,
atients who had persistent atrial fibrillation or flutter or
equired ventricular pacing at the time of MTWA testing
ere excluded. Patients with unstable coronary artery dis-
ase, with New York Heart Association (NYHA) functional
lass IV heart failure, or who were unable to exercise on a
icycle or treadmill also were excluded from the study.
uring the baseline visit, a medical history and a 12-lead
Abbreviations and Acronyms
CI  confidence interval
CMS  Center for Medicare and Medicaid
Services
ICD  implantable cardioverter-defibrillator
LVEF  left ventricular ejection fraction
MADIT  Multicenter Automatic Defibrillator
Implantation Trial
MTWA  microvolt T-wave alternans
NYHA  New York Heart Association
SCD-HeFT  Sudden Cardiac Death in Heart Failure
Triallectrocardiogram were obtained. uTWA testing. Patients had an MTWA exercise test
bicycle or treadmill) while taking their regular cardiovas-
ular medications, including beta-blockers. Careful skin
reparation including mild abrasion and high-resolution
lectrodes (High-Res, Cambridge Heart, Inc., Bedford,
assachusetts) were used to minimize noise. Electrocardio-
raphic leads were placed at the standard 12-lead positions
nd in an orthogonal X, Y, and Z configuration. Measure-
ents were made with CH2000 or Heartwave systems
Cambridge Heart, Inc.) and utilized a spectral method of
nalysis designed to allow detection of alternans in the
icrovolt range of amplitude (14). The MTWA test was
utomatically interpreted within the CH2000 or the Heart-
ave systems by the Alternans Report Classifier (Version
10) and classified according to previously described crite-
ia: MTWA is positive if the onset heart rate is 110
eats/min, negative if the maximum negative heart rate is
105 beats/min, and all others are indeterminate (23). Less
han 10% of the tests classified as indeterminate were
ndeterminate because of technical issues (e.g., noise); the
ast majority (90%) of indeterminate tests were indeter-
inate due to physiologic reasons (ectopy, non-sustained
-wave alternans, or an inability to achieve a heart rate of
05 beats/min) (24). Because previous studies showed that
ositive and indeterminate MTWA tests have similar event
ates (20,23), all comparisons in this analysis were made
etween patients with normal (negative) and abnormal
positive or indeterminate) MTWA tests.
ollow-up. The first scheduled follow-up visit occurred one
onth after the MTWA test. After that, patients were followed
very fourmonths. Follow-up visits focused on reviewing patients’
nterim medical and cardiovascular drug histories.
nd points. As specified in the protocol, all end points
ere adjudicated by an independent external events com-
ittee, which was unaware of the MTWA test results and
hich utilized the modified Hinkle-Thaler classification
25) for the cause of death that was used in MUSTT (5).
he events committee reviewed the primary end point
orms that included a narrative of the event and other data,
s specified in the protocol, pertaining to the event. The
rimary end point used in this study included all-cause
ortality (as recommended by a policy statement on end
oints for trials that include ICDs written by the North
merican Society for Pacing and Electrophysiology) and
on-fatal sustained ventricular arrhythmias (including ICD
hocks with intracardiac electrograms documenting rapid
entricular tachycardia or ventricular fibrillation).
tatistical analyses. We classified MTWA tests as normal
negative) or abnormal (positive or indeterminate). Patient
ata were censored on the date of heart transplantation or
ast follow-up. The time course of the primary end point,
tratified by the results of MTWA, was estimated by the
aplan-Meier method. The association between MTWA
nd the primary end point was assessed using Kaplan-Meier
roduct-limit estimates of the survival functions and tested
sing a log-rank test (26). The 24-month event rate,
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cribe the outcome of patients classified by MTWA, and
ox proportional hazards regression was used to estimate
he hazard ratio and 95% confidence intervals (CIs) (27).
orresponding analyses using Cox regression were per-
ormed taking account of the effect that potential confound-
ng variables may have on the relationship between MTWA
esults and the primary end point. The study protocol
pecified seven potential confounding variables: age, gender,
tiology of heart disease (ischemic vs. non-ischemic cardio-
yopathy), diabetes, and three measures of heart failure
everity at the time of enrollment: NYHA functional class,
VEF, and previous hospital admission for heart failure.
e adjusted for these variables by including each of them
ndividually and collectively as independent variables in Cox
roportional hazards regression models along with MTWA
27). All statistical tests were two-tailed and used an alpha
evel 0.05.
ESULTS
ecruitment. Our study enrolled 587 patients, but 38 of
hese subsequently had a post-enrollment exclusion (pa-
ients who consented to be in the study but withdrew or
ied before MTWA testing). Nearly all of the patients were
ecruited as outpatients; 49% were recruited from academic
eart failure centers, 27% from community-based large
Table 1. Baseline Characteristics for All 549 P
Abnormal Microvolt T-Wave Alternans
Characteristic
A
(n 
Age, yrs 56 
Male 7
White race 5
Ischemic cardiomyopathy 4
Hypertension 5
Current smoker 1
Diabetes mellitus 3
Previous myocardial infarction 4
CABG surgery before enrollment 2
Previous admission for CHF 5
New York Heart Association CHF class
No prior CHF 1
NYHA class I 1
NYHA class II 4
NYHA class III 2
Left ventricular ejection fraction 0.25 
QRS duration 120 ms 2
Drugs at enrollment
Beta-blocker 8
ACE inhibitor/ARB 8
Diuretic 7
Digoxin 5
Anti-lipid 4
All numbers in the table are percentages except for age and LV
for categorical variables are based on chi-square tests.ACE  angiotensin-converting enzyme; ARB  angiotensin
CHF  congestive heart failure; NYHA  New York Heart Assoeneral cardiology private practices, and 24% from other
cademic cardiology groups.
aseline characteristics. The clinical characteristics of
he 549 patients in this study are listed in Table 1; the
ean age was 56 years, 71% were men, 28% had a QRS
uration 120 ms, and the average LVEF was 0.25.
ne-half of the patients had ischemic heart disease, and
he average time from their myocardial infarction was 5
ears. Two-thirds of the patients had NYHA functional
lass II or III heart failure, and more than one-half of the
atients had a prior admission for heart failure. More
han 80% were treated with a beta-blocker and an
ngiotensin-converting enzyme inhibitor or angiotensin
I-receptor blocker. There were few substantial differ-
nces between the normal and abnormal MTWA groups
Table 1).
rimary outcome. Figure 1 shows accrual of the 51 pri-
ary end points (40 deaths and 11 non-fatal sustained
entricular arrhythmias all of which were appropriate ICD
hocks for rapid ventricular arrhythmias) over two years of
ollow-up (mean follow-up of 20 6 months). An MTWA
est was done at baseline and was abnormal in 66% of
articipants. The two-year actuarial event rate was 15.0% in
he patients with an abnormal MTWA test and 2.5% in
hose with a normal test (hazard ratio 6.5, 95% CI 2.4 to
8.1, p 0.001). Only four events occurred in patients with
ts and for the Subgroups With Normal and
Microvolt
T-Wave Alternans
p Value*
Normal
(n  189)
Abnormal
(n  360)
53  9 57  10 0.0001
63 75 0.01
53 52 0.79
50 48 0.71
46 58 0.01
14 10 0.23
30 30 0.85
44 45 0.92
24 29 0.29
52 60 0.09
20 18 0.55
17 16
45 42
19 24
0.26  0.07 0.25  0.06 0.45
21 31 0.01
88 78 0.01
85 88 0.52
69 73 0.38
41 55 0.01
55 46 0.05
p values for continuous variables are based on t tests; p valuesatien
ll
549)
10
1
3
9
4
2
0
5
7
8
8
6
3
2
0.06
8
1
7
2
0
9
EF. *receptor blocker; CABG  coronary artery bypass graft;
ciation.
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ardiac death, and two non-fatal sustained ventricular
rrhythmias.
igure 1. Kaplan-Meier mortality curves for patients with normal versus
bnormal microvolt T-wave alternans (MTWA) test results. In two years of
ollow-up, only 4 events occurred in the 189 patients with a normal MTWA
est; 47 events occurred in the group with an abnormal MTWA test. Abnormal
TWA tests comprise positive tests (n 162, two-year event rate 12.3%) and
ndeterminate tests (n  198, two-year event rate 17.5%).
Table 2. Kaplan-Meier Event Rates and Haza
Variable N 2-Year Eve
MTWA
Abnormal 360 15.
Normal 189 2.
Age (yrs)
65 126 16.
65 421 9.
Gender
Male 390 12.
Female 159 5.
Race
White 289 11.
Non-white 260 10.
Cardiomyopathy
Ischemic 267 12.
Non-ischemic 282 8.
Past CHF admission
Yes 310 14.
No 229 5.
NYHA functional class
II to III 358 12.
II 191 6.
LVEF
0.31 405 12.
0.31 to 0.40 144 7.
QRS duration
120 ms 150 14.
120 ms 394 9.
Beta-blockers
No 100 27.
Yes 434 6.
*p values are based on Wald’s test using estimates from the
CI  confidence interval; CHF  congestive heart failmortality and/or non-fatal sustained ventricular arrhythmias; LVE
T-wave alternans; NYHA  New York Heart Association.CD implants. There were 69 patients who had ICD
mplants (8 before and 61 after enrollment); the actuarial
wo-year implant rate was 14.0% in patients with a normal
TWA test and 13.6% in those with an abnormal test. Of
he ICD implants, 77% were implanted prophylactically
79% in those with a normal MTWA test and 76% in those
ith an abnormal test).
ther risk predictors. Table 2 compares the strength of
ssociation between MTWA and the primary outcome with
ther risk predictors, using univariate hazard ratios as the
easure. The only other variables with hazard ratios 2.0
ere gender, history of hospital admission for heart failure,
nd beta-blocker treatment. All of the other variables in
able 2 had hazard ratios 2.0 and were not statistically
ignificant, although several had borderline significance (i.e.,
values between 0.05 and 0.10). We adjusted MTWA
esults for each of the covariates tabulated in Table 2; in no
nstance did adjustment reduce the hazard ratio for MTWA
elow 6. Adjusted for the seven pre-specified variables
imultaneously (see Methods section), the hazard ratio for
TWA was 5.5 (95% CI 2.0 to 15.3, p  0.001).
nteraction of MTWA with other risk predictors. Table
summarizes our search for interactions between MTWA
nd the other variables listed in Table 2. We found no
tios for Risk Predictors
ate Hazard Ratio (95% CI) p Value*
6.53 (2.35–18.11) 0.001
1.59 (0.88–2.84) 0.120
2.67 (1.20–5.93) 0.016
1.13 (0.65–1.96) 0.670
1.38 (0.79–2.40) 0.254
3.12 (1.56–6.23) 0.001
1.78 (0.93–3.41) 0.079
1.81 (0.88–3.73) 0.105
1.64 (0.93–2.91) 0.088
4.24 (2.43–7.40) 0.001
odels.
ent rate percent of participants who experienced all-causerd Ra
nt R
0
5
0
0
9
3
2
1
6
9
9
1
7
8
0
3
0
2
2
8
Cox m
ure, evF  left ventricular ejection fraction; MTWA  microvolt
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ent risk predictor in all of these subgroups (i.e., has significant
redictive value in both categories of each variable).
Remarkably, in this sample of patients with LVEF
0.40, adjusting for LVEF did not add significantly to the
rognostic information provided by MTWA. When
TWA and LVEF were forced into a multivariate Cox
odel, MTWA remained a strong, independent predictor
f the primary end point (multivariate hazard ratios:
TWA 6.3, p  0.001, and LVEF 1.8; p 0.14). As seen
n Table 3, patients with a normal MTWA test and LVEF
Table 3. Interactions between Microvolt T-W
Variable N MTWA
Age, yrs
65 126 Abnormal
Normal
65 421 Abnormal
Normal
Gender
Male 390 Abnormal
Normal
Female 159 Abnormal
Normal
Race
White 289 Abnormal
Normal
Non-white 260 Abnormal
Normal
Cardiomyopathy
Ischemic 267 Abnormal
Normal
Nonischemic 282 Abnormal
Normal
Previous CHF admission
Yes 310 Abnormal
Normal
No 229 Abnormal
Normal
NYHA functional class
II to III 358 Abnormal
Normal
II 191 Abnormal
Normal
LVEF
0.31 405 Abnormal
Normal
0.31 to 0.40 144 Abnormal
Normal
QRS duration
120 ms 150 Abnormal
Normal
120 ms 394 Abnormal
Normal
Beta-blockers
No 100 Abnormal
Normal
Yes 434 Abnormal
Normal
*p value for testing the equality of hazard ratios is based on
except for LVEF and cardiomyopathy, which are based
†Indeterminate because there were no events in this group.
Abbreviations as in Table 2.0.30 had a lower two-year actuarial event rate (3.5%) than
atients with an abnormal MTWA test and an LVEF
etween 0.31 and 0.40 (11.8%).
ISCUSSION
his study strongly suggests that MTWA testing can
dentify a large group of patients with left ventricular
ysfunction (LVEF0.40) who have an excellent prognosis
nd are unlikely to benefit from ICD prophylaxis. One-
hird of the patients with left ventricular dysfunction re-
lternans and Other Risk Predictors
2-Year
Event Rate
Hazard Ratio
(95% CI) p* Value
20.1
3.7 5.9 (0.8–44.7)
13.0 0.949
2.2 6.4 (2.0–21.0)
17.4
2.8 6.6 (2.0–21.2)
7.8 0.767
1.9 4.5 (0.5–37.3)
15.3
3.2 4.7 (1.4–15.7)
14.5 0.436
1.4 11.9 (1.6–88.5)
16.8
4.8 3.7 (1.3–10.5)
13.3 0.03
0.0 —†
20.1
3.6 6.3 (2.0–20.5)
7.5 0.927
1.2 5.7 (0.7–44.9)
17.7
2.9 6.6 (2.0–21.3)
9.8 0.979
1.5 6.4 (0.8–49.5)
16.1
3.5 5.0 (1.8–14.1)
11.8 0.167
0.0 —†
17.1
5.3 3.2 (0.7–13.9)
13.6 0.319
1.7 9.2 (2.2–38.4)
30.6
15.8 2.2 (0.7–7.5)
10.8 0.098
0.6 16.1 (2.2–118.4)
test of the interaction between each variable and MTWA,
elihood ratio tests. All tests are based on Cox models.ave A
N
93
33
266
155
270
120
90
69
188
101
172
88
173
94
187
95
213
97
141
88
238
120
122
69
271
134
89
55
111
39
244
150
77
23
272
162
Wald’s
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January 17, 2006:456–63 Microvolt T-Wave Alternans and ICD Prophylaxisruited for this study were classified as low risk by a normal
TWA test, and their survival rate at two years was 97.5%.
he sample size of this study was large enough to allow
hysicians to reassure patients with left ventricular dysfunc-
ion and a normal MTWA test that their chance of
xperiencing either death or a sustained ventricular arrhyth-
ia in the next two years is5%, regardless of their LVEF,
tiology of their cardiomyopathy, age, gender, diabetes, or
everity of heart failure. These data extend our initial
ndings from the subset of patients in this study that met
he MADIT II criteria (19).
This natural history study was not complicated by ICD
mplants during the two-year follow-up. Fewer than 15% of
he patients had ICD implants. This low implant rate
implifies interpretation of our results. The implant rate was
lmost identical in the normal and abnormal MTWA
roups (14.0% vs. 13.6%), and, in both groups, about
hree-fourths of the implants were prophylactic. Thus, there
as equal opportunity to observe sustained ventricular
rrhythmias in both groups, avoiding a potential source of
ias. Importantly, appropriate ICD discharges for rapid
entricular arrhythmias were a component of the primary
nd point of this study; only two patients with a normal
-wave alternans test had an appropriate ICD shock in two
ears of follow-up.
The results reported here are consistent with previous
mall studies of MTWA in patients with left ventricular
ysfunction and either ischemic or non-ischemic cardiomy-
pathy. A meta-analysis (20) that included 129 MADIT
I-like patients from two other observational studies (17,18)
eported no sudden cardiac death or cardiac arrest during
wo years of follow-up of patients with a normal MTWA
est, compared with a 15.6% event rate among patients with
n abnormal test (20). Most studies of non-ischemic car-
iomyopathy report a very low event rate in patients with a
ormal MTWA test, although these studies were much too
mall to be definitive (21,22,28).
The MTWA was originally developed in an era where
mplantation of ICDs was restricted to patients with docu-
ented prior sustained ventricular arrhythmias (4,5). Dur-
ng this period, the preliminary focus of risk stratification
as on the positive predictive accuracy of diagnostic tests
sed to identify patients at the highest risk of sudden
ardiac death (such as electrophysiologic testing). This
pproach sacrificed sensitivity for specificity and failed to
dentify a large number of patients at risk for sudden
ardiac death. This approach was also not effective for
atients with non-ischemic cardiomyopathy. Even in
schemic heart disease, the negative predictive accuracy of
his approach was considered unacceptable—12% of pa-
ients with a normal electrophysiology study had a
ustained ventricular arrhythmic event or arrhythmic death
uring two years of follow-up (5).
The MADIT II and SCD-HeFT trials markedly in-
reased the number of patients with left ventricular dysfunc-
ion for which implantation of a prophylactic ICD is undicated and reimbursed by CMS (8,9,11). The beauty of
hese two studies is that they both selected patients for ICD
rophylaxis based on a simple, non-invasive, and widely
vailable diagnostic assessment of LVEF. Unquestionably,
oth studies established a survival benefit for ICD prophy-
axis in patients with left ventricular dysfunction. However,
he absolute risk reduction in these two large studies was
mall. The MADIT II trial showed a 5.6% reduction over
n average follow-up of 20 months; SCD-HeFT found a
.2% reduction at five years of follow-up. Accordingly,
oughly 18 or 14 ICDs must be implanted to save one life,
ut this modest benefit needs to be balanced with the risk of
CD-related adverse events (29,30) and the impact of an
CD on the quality of life (31–33). Previous studies dem-
nstrate that ICD therapy can decrease quality of life due to
variety of problems (31–33). In addition, the economic
urden is significant not only for the patient unnecessarily
reated with an ICD, but also for society at large when
reating so many patients who will not use their ICDs. With
hese issues in mind, the results of the MADIT II and
CD-HeFT trials motivate a search for patients who are
nlikely to benefit from ICD prophylaxis.
The recent recall of defective ICDs has heightened public
wareness to these issues. In our opinion, MTWA testing
ay be useful to physicians and patients who are struggling
ith a decision about replacing a potentially defective
rophylactic ICD. For example, a normal MTWA may tip
he risk-benefit balance in favor of a decision not to change
n ICD that has a low failure rate. Alternatively, an
bnormal MTWA may support a more confident decision
o replace an ICD.
The decision by CMS to cover the cost of an ICD in all
atients who meet the SCD-HeFT criteria will allow
hysicians to judge who should or should not have ICD
rophylaxis. But how are physicians to select patients?
icrovolt T-wave alternans testing is an excellent method
or identifying a subset of patients with left ventricular
ysfunction who are unlikely to experience sustained ven-
ricular tachyarrhythmias and, therefore, unlikely to benefit
rom ICD prophylaxis.
The MTWA is a simple, relatively inexpensive, non-
nvasive test that can be done routinely in a doctor’s office
sing modifications of currently available exercise testing
quipment. Two other practical advantages of MTWA
esting were found in this study. First, the interpretation of
he MTWA tests was generated automatically by the
omputer algorithm in the machine without physician over
ead. Second, MTWA testing was an excellent risk predic-
or even though we conducted the test without withholding
rugs. Our study showed that MTWA had excellent posi-
ive and negative predictive accuracy even in patients taking
eta-blockers. These features of testing add substantially to
he practicality and convenience of testing in busy office
ractices. If MTWA testing were used to exclude a low-risk
ubset of the large population of patients with left ventric-
lar dysfunction, about two-thirds of patients would get
p
h
U
M
i
e
s
t
e
m
m
p
M
M
w
p
a
u
a
s
e
M
C
f
g
m
u
n
p
(
a
w
t
i
A
T
p
o
R
fi
C
S
c
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
462 Bloomfield et al. JACC Vol. 47, No. 2, 2006
Microvolt T-Wave Alternans and ICD Prophylaxis January 17, 2006:456–63rophylactic ICD therapy, but those who did not would
ave minimal risk of experiencing ICD-preventable death.
sing this strategy, among the patients with an abnormal
TWA test, only about seven ICDs would have to be
mplanted to save one life.
There are several limitations to this study. First, it
xcluded patients with persistent atrial fibrillation from the
tudy because MTWA cannot be reliably measured during
his rhythm. Second, the study excluded patients unable to
xercise on a bicycle or treadmill, although MTWA can be
easured during atrial pacing or potentially during a phar-
acologic stress test (14,34). Finally, this study does not
rovide prognostic information beyond two years after the
TWA test. While the negative predictive value of an
TWA test was excellent for the two years after the test,
e cannot predict how long a single normal MTWA test
redicts a very low rate of death or sustained ventricular
rrhythmias. Beyond two years after the MTWA test, an
nknown proportion of patients with a normal T-wave
lternans test may convert to an abnormal T-wave alternans
tatus with much greater risk. Further studies are needed to
valuate this possibility and the potential utility of serial
TWA testing.
onclusions. Among patients with left ventricular dys-
unction, MTWA was able to identify not only a high-risk
roup but also a low-risk group, likely to survive two or
ore years without experiencing death or sustained ventric-
lar arrhythmia. Importantly, because the positive and
egative predictive accuracy of MTWA were similar in
atients with ischemic heart disease and in those with
non-ischemic) cardiomyopathy, clinicians can feel comfort-
ble using MTWA to select patients for ICD prophylaxis
ithout concern for the etiology of left ventricular dysfunc-
ion. Furthermore, MTWA tests are convenient, relatively
nexpensive, and safe (non-invasive).
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